Literature DB >> 21113744

Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.

Yasukazu Sagawa1, Atsuya Fujitoh, Hirotaka Nishi, Hiroe Ito, Tamaki Yudate, Keiichi Isaka.   

Abstract

Using the endometrial cancer cell line EI established in our department, we attempted to establish cisplatin (CDDP)-resistant cell lines by incremental exposure and high concentration exposure methods. Three CDDP-resistant cell lines were isolated, which could be distinguished by morphological differences. 1. Upon acquiring CDDP resistance, the cells tended to become small and grow in a floating state. This tendency was especially marked when using incremental exposure method. Using the incremental exposure method, a cell line obtained by isolating and culturing only adherent cells was designated EICR-Ia, and a cell line established by culturing only floating cells was designated EICR-If. A cell line obtained by the high concentration exposure method was designated EICR-II. 2. Upon acquiring CDDP resistance, tumor markers such as TPA and LDH increased, while proliferative capability of the cells was lowered. 3. The invasion capability was diminished in EICR-If cells, but was increased in EICR-Ia and EICR-II cells. 4. Following exposure to CDDP, the intracellular platinum concentrations were markedly elevated in EI and EICR-If cells, whereas the increase was mild in EICR-Ia and EICR-II cells and the concentration was lower than that in parent EI cells. 5. Studies of drug resistance gene expression revealed increased expression of MDR1, GSTπ, and Topo-II in EICR-If cells; increased expression of GSTπ in EICR-II cells; but no expression of any of the genes in EICR-Ia cells. 6. Analyses of cancer- and apoptosis-related genes showed increased expressions of Bcl-2, c-Myc, p53, and ICE in EICR-If cells. 7. Upon acquiring CDDP resistance, sensitivity to mitomycin and adriamycin decreased, but sensitivity to etoposide and 5-fluorouracil increased. The findings indicate that the mechanisms of CDDP resistance are different in the three cell lines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21113744     DOI: 10.1007/s13277-010-0133-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

Authors:  N A Thornberry; H G Bull; J R Calaycay; K T Chapman; A D Howard; M J Kostura; D K Miller; S M Molineaux; J R Weidner; J Aunins
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

2.  Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms.

Authors:  G V Glinsky; V V Glinsky; A B Ivanova; C J Hueser
Journal:  Cancer Lett       Date:  1997-05-19       Impact factor: 8.679

3.  Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy.

Authors:  G Deppe; C J Cohen; H W Bruckner
Journal:  Gynecol Oncol       Date:  1980-08       Impact factor: 5.482

Review 4.  Chemotherapy of metastatic endometrial cancer.

Authors:  H B Muss
Journal:  Semin Oncol       Date:  1994-02       Impact factor: 4.929

5.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

6.  Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.

Authors:  W R Waud; S D Harrison; K S Gilbert; W R Laster; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.

Authors:  J T Thigpen; J A Blessing; L D Lagasse; P J DiSaia; H D Homesley
Journal:  Am J Clin Oncol       Date:  1984-06       Impact factor: 2.339

8.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

9.  Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.

Authors:  B H Xu; V Gupta; S V Singh
Journal:  Arch Biochem Biophys       Date:  1994-01       Impact factor: 4.013

10.  Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.

Authors:  J F Belliveau; M R Posner; L Ferrari; G W Crabtree; F J Cummings; M C Wiemann; G P O'Leary; H Griffin; M A Phaneuf; A O'Rourke
Journal:  Cancer Treat Rep       Date:  1986-10
View more
  6 in total

1.  Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.

Authors:  Kazuhiko Shien; Shinichi Toyooka; Hiromasa Yamamoto; Junichi Soh; Masaru Jida; Kelsie L Thu; Shinsuke Hashida; Yuho Maki; Eiki Ichihara; Hiroaki Asano; Kazunori Tsukuda; Nagio Takigawa; Katsuyuki Kiura; Adi F Gazdar; Wan L Lam; Shinichiro Miyoshi
Journal:  Cancer Res       Date:  2013-03-29       Impact factor: 12.701

2.  Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.

Authors:  Toshimitsu Yamaoka; Motoi Ohba; Satoru Arata; Tohru Ohmori
Journal:  J Vis Exp       Date:  2017-08-11       Impact factor: 1.355

3.  Metadherin confers chemoresistance of cervical cancer cells by inducing autophagy and activating ERK/NF-κB pathway.

Authors:  Jingwei Zhang; Yunyan Zhang; Shuang Liu; Qingmeng Zhang; Yan Wang; Liping Tong; Xiaohang Chen; Yuting Ji; Qinglong Shang; Baozhan Xu; Ming Chu; Lanlan Wei
Journal:  Tumour Biol       Date:  2013-04-18

Review 4.  Hematologic malignancies: newer strategies to counter the BCL-2 protein.

Authors:  Abdul Shukkur Ebrahim; Hussam Sabbagh; Allison Liddane; Ali Raufi; Mustapha Kandouz; Ayad Al-Katib
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-04       Impact factor: 4.553

5.  Spontaneous Cell Detachment and Reattachment in Cancer Cell Lines: An In Vitro Model of Metastasis and Malignancy.

Authors:  Elena Vargas-Accarino; Carlos Herrera-Montávez; Santiago Ramón Y Cajal; Trond Aasen
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

6.  TALEN-mediated Nanog disruption results in less invasiveness, more chemosensitivity and reversal of EMT in Hela cells.

Authors:  Yan Ding; Ai Qing Yu; Cheng Lin Li; Juan Fang; Yi Zeng; Dong Sheng Li
Journal:  Oncotarget       Date:  2014-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.